Head to Head Contrast: Coya Therapeutics (COYA) versus Its Peers

Coya Therapeutics (NASDAQ:COYA) is one of 985 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Coya Therapeutics to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Volatility & Risk

Coya Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Coya Therapeutics’ competitors have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.

Earnings & Valuation

This table compares Coya Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coya Therapeutics	$6.00 million	-$7.99 million	-10.73
Coya Therapeutics Competitors	$8.48 billion	$141.08 million	-4.57

Coya Therapeutics’ competitors have higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Coya Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	N/A	-42.53%	-37.57%
Coya Therapeutics Competitors	-2,611.00%	-224.76%	-28.17%

Analyst Recommendations

This is a breakdown of recent recommendations for Coya Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	0	0	2	0	3.00
Coya Therapeutics Competitors	6199	18302	43931	892	2.57

Coya Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 67.26%. As a group, “Pharmaceutical preparations” companies have a potential upside of 78.05%. Given Coya Therapeutics’ competitors higher probable upside, analysts clearly believe Coya Therapeutics has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 9.8% of Coya Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Coya Therapeutics competitors beat Coya Therapeutics on 9 of the 13 factors compared.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.